Background: Although high resting heart rates are associated with adverse outcomes in heart failure with reduced ejection, the reports for heart failure with preserved ejection fraction (HFpEF) are conflicting. Design: A secondary analysis was conducted in order to examine the relationship between resting heart rate and adverse outcomes in 2705 patients (mean age ¼ 68 AE 10 years; 47% men; 88% white) with HFpEF who were in sinus rhythm from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). Methods: Baseline heart rate was obtained from baseline electrocardiogram data. Outcomes were adjudicated by a clinical end-point committee and included the following factors: hospitalisation, hospitalisation for heart failure, death and cardiovascular death. Results: Over a median follow-up of 3.4 years (25th-75th percentiles ¼ 2.0-4.9 years), a total of 1157 hospitalisations, 311 hospitalizations for heart failure, 369 deaths and 233 cardiovascular deaths occurred. An increased risk (per 5-beats per minute [bpm] increase) for hospitalisation (hazard ratio [HR] ¼ 1.03, 95% confidence interval [CI] ¼ 1.004-1.060), hospitalisation for heart failure (HR ¼ 1.10, 95% CI ¼ 1.05-1.15), death (HR ¼ 1.10, 95% CI ¼ 1.06-1.16) and cardiovascular death (HR ¼ 1.13, 95% CI ¼ 1.07-1.19) was observed. When the analysis was limited to those who did not report the use of b-blockers, the magnitude of the association for each outcome (per 5-bpm increase) was not materially altered (hospitalisation: HR ¼ 1.03, 95% CI ¼ 0.97-1.09; hospitalisation for heart failure: HR ¼ 1.12, 95% CI ¼ 0.98-1.27; death: HR ¼ 1.16, 95% CI ¼ 1.05-1.28; cardiovascular death: HR ¼ 1.12, 95% CI ¼ 0.99-1.27). Conclusion: High resting heart rate is a risk factor for adverse outcomes in patients with HFpEF, and future studies are needed in order to determine whether reducing heart rate improves outcomes in HFpEF.
Introduction
In patients with heart failure with reduced ejection fraction, high resting heart rates represent increased neurohormonal activation, as the heart tries to compensate for its inability to pump effectively. 1 Accordingly, heart rate has been shown to be an important predictor of adverse cardiovascular outcomes in patients with reduced ejection fraction. 2 Additionally, therapies that aim to reduce resting heart rates are associated with a lower risk of cardiovascular death and hospitalisation for heart failure in this high-risk group.
Although the inherent risk of adverse events associated with high resting heart rates and the benefits of heart rate reduction have been clearly demonstrated in heart failure with reduced ejection fraction, [3] [4] [5] the impact of heart rate on outcomes in heart failure with preserved ejection fraction (HFpEF) is less clear. Studies have suggested that high resting heart rates in HFpEF are associated with an increased risk of mortality, 6, 7 while others have reported a null association. 8, 9 Similar inconsistencies exist for the relationship between resting heart rate and the risk of hospitalisation for heart failure. 7, 8 Therefore, a closer examination of heart rate and adverse outcomes in HFpEF is warranted, and we explored this relationship in HFpEF patients from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT).
Methods

Study design and patients
TOPCAT was a multicentre, international randomised, double-blind, placebo-control study examining the efficacy of spironolactone in patients with HFpEF. The design, inclusion criteria and baseline characteristics of the trial have been published previously. 10, 11 Briefly, 3445 patients with symptomatic HFpEF from 270 sites in six countries were enrolled between August 2006 and January 2012. The primary goal of the trial was to determine whether spironolactone was associated with a reduction in the composite outcome of cardiovascular mortality, aborted cardiac arrest or heart failure hospitalisation in patients with HFpEF (e.g. documented ejection fraction !45%).
We examined the relationship between resting heart rate obtained on the baseline 12-lead electrocardiogram and the risk of hospitalisation, hospitalisation for heart failure, death and cardiovascular death. We excluded TOPCAT participants who had evidence of non-sinus rhythm (e.g. atrial fibrillation) during the baseline electrocardiogram recording.
Baseline characteristics
Patients who participated in TOPCAT underwent a detailed baseline visit in order to obtain medical histories and a physical examination was performed. 11 Heart rate in beats per minutes (bpm) was obtained from the 12-lead electrocardiogram performed at the baseline study visit after participants rested in the supine position for 5 minutes. Age, sex, race and smoking status were obtained by self-reported history. Smoking was defined as the current use of cigarettes.
Medical histories for the following diagnoses were obtained by self-report and medical record review: diabetes, coronary heart disease, stroke, New York Heart Association class and prior heart failure hospitalisation. Systolic blood pressure and body mass index were obtained by trained staff and laboratory data included serum creatinine. Medication data were also obtained during the initial study visit and the following were included in this analysis: aspirin, b-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and statins.
Outcomes
Outcomes in TOPCAT were adjudicated by a clinical end-point committee, and the details of this process and definitions for each examined outcome have been described. 10, 12 The outcomes examined in this analysis included hospitalisation, hospitalisation for heart failure, death and cardiovascular death. Briefly, hospitalisation for heart failure was defined as the unexpected presentation to an acute care facility requiring overnight stay with symptoms and physical examination findings consistent with heart failure, and treatment with intravenous vasodilators, inotropes, mechanical fluid removal or haemodynamic support. Cardiovascular death was defined as death due to one of the following: myocardial infarction, worsening heart failure, sudden death, stroke, pulmonary embolism, death occurring during a cardiovascular-related procedure or other cardiovascular death. Death included the composite of cardiovascular and noncardiovascular death.
Statistics
Heart rate was categorised across quartiles of the baseline distribution (quartile 1: <59 bpm; quartile 2: 59-64 bpm; quartile 3: 65-73 bpm; quartile 4: !74 bpm). Baseline characteristics were compared across heart rate categories. Categorical variables were reported as frequencies and percentages, while continuous variables were recorded as means AE SDs. Statistical significance for categorical variables was tested using the 2 method and statistical significance for continuous variables was tested using the analysis of variance procedure. Followup time was defined as the time from randomisation until one of the following: outcome of interest, death, loss to follow-up or end of follow-up. Kaplan-Meier estimates were used in order to examine the unadjusted cumulative incidence estimates of each outcome associated with each heart rate category. Incidence rates per 100 person-years were computed for each event. Cox regression was used in order to examine the risk of each outcome associated with each heart rate category (referent: quartile 1). Multivariable models were constructed as follows: model 1 adjusted for age, sex and race; model 2 adjusted for model 1 covariates plus smoking, systolic blood pressure, diabetes, body mass index, serum creatinine, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, b-blockers, statins, randomisation group (spironolactone versus placebo), New York Heart Association class, coronary heart disease and stroke. The risk of each outcome was also examined using heart rate as a continuous variable (per 5-bpm increase). Several sensitivity analyses were performed. Due to the fact that b-blockers directly influence heart rate, a secondary analysis was performed in which the analysis was stratified by b-blocker use. Data from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) have suggested that heart failure patients with heart rates !70 bpm benefit from further reductions in heart rate. 3 Accordingly, a secondary analysis was performed in order to examine the risk of each outcome in patients with heart rates !70 versus those with heart rates <70 bpm. Additionally, due to differences in the baseline characteristics and event rates observed between patients recruited in Russia and Georgia versus the Americas, 13 we examined whether our findings varied by region (Russia/ Georgia vs. the Americas). Statistical significance was defined as p < 0.05. SAS Version 9.4 (Cary, NC, USA) was used for all analyses.
Results
A total of 2705 patients (mean age ¼ 68 AE 10 years; 47% men; 88% white) were included in the final analytical sample. The mean heart rate was 67 AE 11 bpm, and the distribution of heart rates for the study cohort is shown in Figure 1 . Baseline characteristics across heart rate quartiles are shown in Table 1 .
Over a median follow-up of 3.4 years (25th-75th percentiles ¼ 2.0-4.9 years), a total of 1157 hospitalisations, 311 hospitalisations for heart failure, 369 deaths and 233 cardiovascular deaths occurred. Higher cumulative incidence estimates for all outcomes were observed in patients as heart rate quartile increased ( Table 2 ). The cumulative incidence estimates for hospitalisation and death are depicted in Figures 2 and 3 , respectively.
An increased risk for hospitalisation, hospitalisation for heart failure, death and cardiovascular death was observed for those with higher compared with lower heart rates ( Table 2) . Additionally, the results were similar when heart rate was examined as a continuous variable per 5-bpm increase. When the analysis was stratified by b-blocker use, the magnitude of the association for each outcome (per 5-bpm increase) did not vary between groups (Table 3) . In addition, when we explored the utility of the clinical cut-off point of 70 bpm for resting heart rate, an increased risk of hospitalisation for heart failure, death and cardiovascular death was observed ( Table 4 ). The association between heart rate and each outcome remained similar when the analysis was stratified by country of origin (Supplemental Table 1 ).
Discussion
In this analysis from TOPCAT, we have demonstrated that higher resting heart rates are associated with an increased risk of adverse outcomes in patients with HFpEF who are in sinus rhythm. Specifically, we have shown that the risk of hospitalisation, hospitalisation for heart failure, death and cardiovascular death increases linearly across heart rate values. Overall, our findings suggest that elevated heart rates have important prognostic significance in HFpEF, and careful clinical evaluation is needed in HFpEF patients with heart rates !70 bpm.
Despite numerous reports that have demonstrated that high resting heart rates are associated with adverse outcomes among heart failure patients with reduced ejection, 2-4 the reports for HFpEF patients are conflicting. In a subgroup analysis limited to HFpEF patients from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity Program, resting heart rate (per 10-bpm increase) was not associated with all-cause mortality (hazard ratio [HR] ¼ 1.05, 95% confidence interval [CI] ¼ 0.98-1.12). 6 A trend for significance was observed between heart rate (per 10-bpm increase) and the composite of cardiovascular death and hospitalisation for heart failure (HR ¼ 1.06, 95% CI ¼ 1.00-1.12). Data from the Irbesartan in Patients with Heart Failure and Preserved Systolic Function Trial (I-Preserve) demonstrated that higher resting heart rates per 1-SD increase were associated with cardiovascular death (HR ¼ 1.12, 95% CI ¼ 1.01-1.24), but not all-cause mortality (HR ¼ 1.08, 95% CI ¼ 0.99-1.18). 9 Similarly, data from the Digitalis Investigator Group (DIG) trial demonstrated that higher resting heart rates (quartile 4 vs. quartile 2: HR ¼ 1.38, 95% CI ¼ 0.94-2.02) were not associated with mortality in HFpEF patients. 8 In contrast, data from the Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2) study linked higher resting heart rate with all-cause mortality (quartile 3 vs. quartile 1: HR ¼ 1.82, 95% CI ¼ 1.23-2.69) and cardiovascular death (quartile 3 vs. quartile 1: HR ¼ 1.98, 95% CI ¼ 1.05-3.72). Similar inconsistencies exist for the relationship between heart rate and the risk of hospitalisation for heart failure. [7] [8] [9] In contrast, the current analysis was able to demonstrate that higher resting heart rates are associated with an increased risk of several outcomes in patients with HFpEF. Due to the robust ascertainment of outcomes in TOPCAT, we were able to examine the individual risks for several outcomes, and this was not done in prior reports. Furthermore, the current analysis was limited to patients with HFpEF, and we did not have to stratify between reduced and preserved ejection fraction, as was done in several of the aforementioned studies. [6] [7] [8] Additionally, compared with prior reports, our analysis was limited to participants in sinus rhythm, 6 included an international sample 7 and did not precede contemporary heart failure management. 8, 9 Therefore, our data likely provide a more accurate assessment of the association between heart rate and outcomes in HFpEF patients.
b-blocker therapy has consistently been shown to improve survival rates in patients with heart failure with reduced ejection fraction, presumably through inhibition of the sympathetic nervous system and subsequent prevention of adverse myocardial remodelling through reductions in heart rate. 5, 14 Recently, data have demonstrated that patients with reduced ejection fractions who have persistent heart rates above 70 bpm, despite adequate b-blocker therapy, benefit from agents that selectively reduce heart rate. 3 Accordingly, ivabradine is recommended for symptomatic patients with reduced ejection fractions (<35%) on optimal b-blocker therapy who have heart rates !70 bpm in sinus rhythm. 15 Although similar recommendations do not exist for HFpEF, our data demonstrate that a significant risk of hospitalisation for heart failure, death and cardiovascular death exists in HFpEF patients with heart rates !70 bpm. Therefore, it is possible that a similar benefit in heart rate-reductive strategies exists in HFpEF patients. Additionally, we observed a similar increased risk of adverse events with higher resting heart rates in patients who did and did not receive b-blockers. This would suggest that heart rate goals are more beneficial in HFpEF than the presence of b-blockade therapy. However, the secondary analyses in this report were strictly exploratory and further research, including clinical trials, is needed before changes in clinical practice can be recommended. The current study should be interpreted in the context of certain limitations. The study sample was limited to patients in sinus rhythm, which limits the generalisability of our findings. Several baseline characteristics were obtained by self-report and subjected our analysis to recall bias. Similarly, although a rigorous methodology was used in order to ascertain all of the outcomes, it is possible that events were missed.
Heart rate was measured at one visit and it is possible that the results could change with subsequent heart rate recordings. However, the aim of this study was to demonstrate that heart rate measurements at a single point in time are predictive of adverse events in HFpEF patients. Additionally, significant results were not observed for hospitalisation, hospitalisation for heart failure and cardiovascular death in patients who did not report the use of b-blocker therapies. Despite a lack of statistical significance that was related to the small number of patients who did not receive b-blockers, the effect estimates were similar to those of patients who received these therapies, suggesting that a comparable association exists in the two groups. Lastly, we attempted to account for differences between study participants in our multivariable models, but acknowledge the possibility of residual confounding.
In conclusion, higher resting heart rates are associated with several adverse events in patients with HFpEF. Further studies are needed in order to confirm our findings and to explore the possibility of heart rate reduction strategies for improving outcomes in patients with HFpEF.
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